XENCOR INC (XNCR) Stock News

12 Health Care Stocks Moving In Friday's After-Market Session

Mentions: WORX MTNB VYGR AQB ...

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead Sciences (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S. and internationally. The 52-week range of Gilead Sciences stock price was $62.07 to ...

Mentions: GILD VZ AMZN WMT ...

Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of -4.76% and 48.38%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mentions: AKBA

Xencor Reports First Quarter 2025 Financial Results

Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mentions: CPRX

Critical Insights From Xencor Analyst Ratings: What You Need To Know

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Xencor Appoints Todd Simpson to Board of Directors

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xencor (NASDAQ:XNCR) just reported results for the second quarter of 2024.Xenco...

Xencor to Participate at Upcoming Investor Conferences

Xencor Reports Third Quarter 2024 Financial Results

XNCR Stock Earnings: Xencor Misses EPS, Beats Revenue for Q2 2024

XNCR stock results show that Xencor missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Xencor Announces Upcoming Change to Board of Directors

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Xencor Announces Proposed Public Offering of Common Stock

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

Xencor Reports Second Quarter 2024 Financial Results

Xencor Regains CD20 x CD3 Bispecific T-Cell Engager

XNCR Stock Earnings: Xencor Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xencor (NASDAQ:XNCR) just reported results for the first quarter of 2024.Xencor...